内容紹介
Summary
Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria(irRC)have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors(RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.
要旨
がんワクチン療法をはじめとするがん免疫療法は抗原特異的免疫応答の賦活後,抗腫瘍効果を示すと考えられている。がん免疫療法の特性を考慮した臨床効果判定として,化学療法に用いられるResponse Evaluation Criteria in Solid Tumors(RECIST)に代わり,近年immune-related response criteria(irRC)が用いられる。これまで当教室で経験したがんワクチン臨床試験参加91例に対してはRECISTを主に使用してきたが,今回はirRCによる再解析を実施した。その結果,PDからPRおよびPDからSDと評価が異なった2例を経験した。これら2例は長期生存を果たしたことから,免疫療法におけるirRC評価の妥当性が示された。
目次
Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria(irRC)have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors(RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.
要旨
がんワクチン療法をはじめとするがん免疫療法は抗原特異的免疫応答の賦活後,抗腫瘍効果を示すと考えられている。がん免疫療法の特性を考慮した臨床効果判定として,化学療法に用いられるResponse Evaluation Criteria in Solid Tumors(RECIST)に代わり,近年immune-related response criteria(irRC)が用いられる。これまで当教室で経験したがんワクチン臨床試験参加91例に対してはRECISTを主に使用してきたが,今回はirRCによる再解析を実施した。その結果,PDからPRおよびPDからSDと評価が異なった2例を経験した。これら2例は長期生存を果たしたことから,免疫療法におけるirRC評価の妥当性が示された。